Literature DB >> 29316175

Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial.

Bjørn H Ebdrup1,2, Brian V Broberg1, Pelle L Ishøy1, Nikolaj Bak1, Ulrik B Andersen3, Niklas R Jørgensen4,5, Jens J Holst6, Filip K Knop2,6,7, Birte Y Glenthøj1,2.   

Abstract

Entities:  

Year:  2018        PMID： 29316175      PMCID： PMC6885958          DOI： 10.1111/dom.13204

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN： 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  2 in total

1.  Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).

Authors:  Dan J Siskind; Anthony W Russell; Clare Gamble; Karl Winckel; Karla Mayfield; Sam Hollingworth; Ingrid Hickman; Victor Siskind; Steve Kisely
Journal:  Diabetes Obes Metab       Date:  2017-12-19       Impact factor: 6.577

2.  Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.

Authors:  Pelle L Ishøy; Filip K Knop; Brian V Broberg; Nikolaj Bak; Ulrik B Andersen; Niklas R Jørgensen; Jens J Holst; Birte Y Glenthøj; Bjørn H Ebdrup
Journal:  Diabetes Obes Metab       Date:  2016-11-14       Impact factor: 6.577
  2 in total
  1 in total

Review 1.  Pharmacological interventions for prevention of weight gain in people with schizophrenia.

Authors:  Sri Mahavir Agarwal; Nicolette Stogios; Zohra A Ahsan; Jonathan T Lockwood; Markus J Duncan; Hiroyoshi Takeuchi; Tony Cohn; Valerie H Taylor; Gary Remington; Guy E J Faulkner; Margaret Hahn
Journal:  Cochrane Database Syst Rev       Date:  2022-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.